In late 2015 and early 2016, the first dengue vaccine, Dengvaxia (CYD-TDV) by Sanofi Pasteur, was registered in several countries for use in individuals 9–45 years of age living in endemic areas.
A finais de 2015 e inicios de 2016, rexistrouse en varios países a primeira vacina do dengue, Dengvaxia (CYD-TDV) de Sanofi Pasteur, para uso en individuos de 9 a 45 anos que vivan en áreas endémicas.